Longitudinal Assessment of Immune Response and Viral Characteristics in HIV-Infected Patients with Prolonged CD4+/Viral Load Discordance
- 1 January 2005
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 21 (1) , 13-16
- https://doi.org/10.1089/aid.2005.21.13
Abstract
Although suppression of HIV-1 RNA below the limit of detection is associated with optimal outcomes, many patients can maintain or increase their CD4+ count for prolonged time periods in the presence of persistent low-level viremia. We followed seven patients with prolonged (>5 years) discordant CD4+/viral load (VL) responses on protease inhibitor (PI)-based highly active antiretroviral therapy (HAART) prospectively for 1 year to assess evolution of immune function, viral phenotype, replication capacity (RC), and resistance profile. Immune function was assessed by qualitative and quantitative measurement of cellular activation (CD38+HLA-DR+ and CD38 antibodies bound per cell), and the interferon (IFN)-γ ELISpot assay. Presence of syncytium-inducing (SI) or nonsyncytium-inducing (NSI) viral strains was determined by MT-2 cell culture. RC was measured by a modified rapid recombinant virus assay. The resistance profile was characterized by both genotypic and phenotypic analysis. Over the year of follow-up, IFN-γ production to gag persisted, responses to other HIV antigens increased, and markers of cellular activation did not change. NSI virus predominated. The genotypic (GSS) and phenotypic (PSS) susceptibility scores remained stable. Evolution of RC was variable over the year of follow-up, but the RC of viruses remained well below that of wild-type clinical isolates. Thus, CD4+/VL discordance can be maintained for periods exceeding 5 years in some patients receiving PI-based HAART without significant evolution of HIV resistance.Keywords
This publication has 11 references indexed in Scilit:
- Strong Cell‐Mediated Immune Responses Are Associated with the Maintenance of Low‐Level Viremia in Antiretroviral–Treated Individuals with Drug‐Resistant Human Immunodeficiency Virus Type 1The Journal of Infectious Diseases, 2004
- Prolonged CD4+Cell/Virus Load Discordance during Treatment with Protease Inhibitor–Based Highly Active Antiretroviral Therapy: Immune Response and Viral ControlThe Journal of Infectious Diseases, 2003
- Evolution of Phenotypic Drug Susceptibility and Viral Replication Capacity during Long-Term Virologic Failure of Protease Inhibitor Therapy in Human Immunodeficiency Virus-Infected AdultsJournal of Virology, 2002
- Molecular Mechanisms of Resistance to Human Immunodeficiency Virus Type 1 with Reverse Transcriptase Mutations K65R and K65R+M184V and Their Effects on Enzyme Function and Viral Replication CapacityAntimicrobial Agents and Chemotherapy, 2002
- Nelfinavir-Resistant, Amprenavir-Hypersusceptible Strains of Human Immunodeficiency Virus Type 1 Carrying an N88S Mutation in Protease Have Reduced Infectivity, Reduced Replication Capacity, and Reduced Fitness and Process the Gag Polyprotein Precursor AberrantlyJournal of Virology, 2002
- Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutationsJournal of Medical Virology, 2001
- Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable ViremiaNew England Journal of Medicine, 2001
- Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral TherapyAnnals of Internal Medicine, 2000
- The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis PlanAntiviral Therapy, 2000